vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and GLOBAL INDUSTRIAL Co (GIC). Click either name above to swap in a different company.
GLOBAL INDUSTRIAL Co is the larger business by last-quarter revenue ($345.6M vs $183.1M, roughly 1.9× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 4.2%, a 9.1% gap on every dollar of revenue. On growth, GLOBAL INDUSTRIAL Co posted the faster year-over-year revenue change (14.3% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $19.2M). Over the past eight quarters, GLOBAL INDUSTRIAL Co's revenue compounded faster (3.4% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Global Industrial Company is a Port Washington, New York–based company providing industrial and MRO products through a system of branded e-Commerce websites and relationship marketers in North America. The primary brand is Global Industrial.
AMPH vs GIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $345.6M |
| Net Profit | $24.4M | $14.6M |
| Gross Margin | 46.8% | 34.5% |
| Operating Margin | 19.4% | 5.7% |
| Net Margin | 13.3% | 4.2% |
| Revenue YoY | -1.8% | 14.3% |
| Net Profit YoY | -35.7% | 36.4% |
| EPS (diluted) | $0.51 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $345.6M | ||
| Q3 25 | $191.8M | $353.6M | ||
| Q2 25 | $174.4M | $358.9M | ||
| Q1 25 | $170.5M | $321.0M | ||
| Q4 24 | $186.5M | $302.3M | ||
| Q3 24 | $191.2M | $342.4M | ||
| Q2 24 | $182.4M | $347.8M | ||
| Q1 24 | $171.8M | $323.4M |
| Q4 25 | $24.4M | $14.6M | ||
| Q3 25 | $17.4M | $18.8M | ||
| Q2 25 | $31.0M | $25.1M | ||
| Q1 25 | $25.3M | $13.6M | ||
| Q4 24 | $38.0M | $10.7M | ||
| Q3 24 | $40.4M | $16.8M | ||
| Q2 24 | $37.9M | $20.3M | ||
| Q1 24 | $43.2M | $13.2M |
| Q4 25 | 46.8% | 34.5% | ||
| Q3 25 | 51.4% | 35.6% | ||
| Q2 25 | 49.6% | 37.1% | ||
| Q1 25 | 50.0% | 34.9% | ||
| Q4 24 | 46.5% | 33.8% | ||
| Q3 24 | 53.3% | 34.0% | ||
| Q2 24 | 52.2% | 35.2% | ||
| Q1 24 | 52.4% | 34.3% |
| Q4 25 | 19.4% | 5.7% | ||
| Q3 25 | 13.2% | 7.4% | ||
| Q2 25 | 24.2% | 9.3% | ||
| Q1 25 | 21.9% | 5.7% | ||
| Q4 24 | 24.2% | 4.8% | ||
| Q3 24 | 29.8% | 6.5% | ||
| Q2 24 | 30.3% | 7.6% | ||
| Q1 24 | 27.9% | 5.4% |
| Q4 25 | 13.3% | 4.2% | ||
| Q3 25 | 9.0% | 5.3% | ||
| Q2 25 | 17.8% | 7.0% | ||
| Q1 25 | 14.8% | 4.2% | ||
| Q4 24 | 20.4% | 3.5% | ||
| Q3 24 | 21.1% | 4.9% | ||
| Q2 24 | 20.8% | 5.8% | ||
| Q1 24 | 25.1% | 4.1% |
| Q4 25 | $0.51 | $0.37 | ||
| Q3 25 | $0.37 | $0.48 | ||
| Q2 25 | $0.64 | $0.65 | ||
| Q1 25 | $0.51 | $0.35 | ||
| Q4 24 | $0.74 | $0.28 | ||
| Q3 24 | $0.78 | $0.44 | ||
| Q2 24 | $0.73 | $0.52 | ||
| Q1 24 | $0.81 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $67.5M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $313.2M |
| Total Assets | $1.6B | $580.8M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $67.5M | ||
| Q3 25 | $276.2M | $67.2M | ||
| Q2 25 | $231.8M | $55.1M | ||
| Q1 25 | $236.9M | $39.0M | ||
| Q4 24 | $221.6M | $44.6M | ||
| Q3 24 | $250.5M | $38.9M | ||
| Q2 24 | $217.8M | $38.8M | ||
| Q1 24 | $289.6M | $29.9M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $313.2M | ||
| Q3 25 | $776.7M | $316.0M | ||
| Q2 25 | $757.5M | $305.2M | ||
| Q1 25 | $751.3M | $287.9M | ||
| Q4 24 | $732.3M | $281.1M | ||
| Q3 24 | $727.7M | $279.2M | ||
| Q2 24 | $713.3M | $270.4M | ||
| Q1 24 | $672.4M | $260.2M |
| Q4 25 | $1.6B | $580.8M | ||
| Q3 25 | $1.7B | $602.5M | ||
| Q2 25 | $1.6B | $586.5M | ||
| Q1 25 | $1.6B | $536.7M | ||
| Q4 24 | $1.6B | $520.7M | ||
| Q3 24 | $1.5B | $531.6M | ||
| Q2 24 | $1.5B | $542.5M | ||
| Q1 24 | $1.6B | $517.4M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $20.0M |
| Free Cash FlowOCF − Capex | $24.6M | $19.2M |
| FCF MarginFCF / Revenue | 13.4% | 5.6% |
| Capex IntensityCapex / Revenue | 4.5% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.37× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $74.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $20.0M | ||
| Q3 25 | $52.6M | $22.7M | ||
| Q2 25 | $35.6M | $31.7M | ||
| Q1 25 | $35.1M | $3.4M | ||
| Q4 24 | $29.0M | $15.9M | ||
| Q3 24 | $60.0M | $9.6M | ||
| Q2 24 | $69.1M | $18.8M | ||
| Q1 24 | $55.3M | $6.4M |
| Q4 25 | $24.6M | $19.2M | ||
| Q3 25 | $47.2M | $22.0M | ||
| Q2 25 | $25.0M | $30.3M | ||
| Q1 25 | $24.4M | $3.2M | ||
| Q4 24 | $16.6M | $15.2M | ||
| Q3 24 | $46.2M | $8.7M | ||
| Q2 24 | $63.1M | $17.9M | ||
| Q1 24 | $46.5M | $5.1M |
| Q4 25 | 13.4% | 5.6% | ||
| Q3 25 | 24.6% | 6.2% | ||
| Q2 25 | 14.3% | 8.4% | ||
| Q1 25 | 14.3% | 1.0% | ||
| Q4 24 | 8.9% | 5.0% | ||
| Q3 24 | 24.1% | 2.5% | ||
| Q2 24 | 34.6% | 5.1% | ||
| Q1 24 | 27.1% | 1.6% |
| Q4 25 | 4.5% | 0.2% | ||
| Q3 25 | 2.8% | 0.2% | ||
| Q2 25 | 6.1% | 0.4% | ||
| Q1 25 | 6.3% | 0.1% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.3% | ||
| Q1 24 | 5.1% | 0.4% |
| Q4 25 | 1.35× | 1.37× | ||
| Q3 25 | 3.03× | 1.21× | ||
| Q2 25 | 1.15× | 1.26× | ||
| Q1 25 | 1.39× | 0.25× | ||
| Q4 24 | 0.76× | 1.49× | ||
| Q3 24 | 1.48× | 0.57× | ||
| Q2 24 | 1.82× | 0.93× | ||
| Q1 24 | 1.28× | 0.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GIC
Segment breakdown not available.
